Found: 34
Select item for more details and to access through your institution.
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-05492-5
- By:
- Publication type:
- Article
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 2, p. 1, doi. 10.1002/jmv.28452
- By:
- Publication type:
- Article
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 10, p. 1315, doi. 10.1111/apt.18229
- By:
- Publication type:
- Article
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
- Published in:
- Hepatology Research, 2023, v. 53, n. 10, p. 960, doi. 10.1111/hepr.13936
- By:
- Publication type:
- Article
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight.
- Published in:
- Hepatology Research, 2023, v. 53, n. 7, p. 595, doi. 10.1111/hepr.13899
- By:
- Publication type:
- Article
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients.
- Published in:
- Hepatology Research, 2022, v. 52, n. 7, p. 586, doi. 10.1111/hepr.13768
- By:
- Publication type:
- Article
Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 7, p. 603, doi. 10.1111/hepr.13765
- By:
- Publication type:
- Article
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
- Published in:
- Hepatology Research, 2022, v. 52, n. 6, p. 508, doi. 10.1111/hepr.13757
- By:
- Publication type:
- Article
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
- Published in:
- Hepatology Research, 2021, v. 51, n. 9, p. 979, doi. 10.1111/hepr.13693
- By:
- Publication type:
- Article
Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19.
- Published in:
- Hepatology Research, 2020, v. 50, n. 10, p. 1196, doi. 10.1111/hepr.13551
- By:
- Publication type:
- Article
High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C.
- Published in:
- Hepatology Research, 2020, v. 50, n. 6, p. 671, doi. 10.1111/hepr.13490
- By:
- Publication type:
- Article
Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 12, p. 3257, doi. 10.3390/cancers15123257
- By:
- Publication type:
- Article
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 593, doi. 10.3390/cancers15030593
- By:
- Publication type:
- Article
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3938, doi. 10.3390/cancers14163938
- By:
- Publication type:
- Article
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 232, doi. 10.3390/cancers14010232
- By:
- Publication type:
- Article
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
- Published in:
- Cancers, 2021, v. 13, n. 14, p. 3633, doi. 10.3390/cancers13143633
- By:
- Publication type:
- Article
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
- Published in:
- PLoS ONE, 2021, v. 16, n. 3, p. 1, doi. 10.1371/journal.pone.0247728
- By:
- Publication type:
- Article
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000527759
- By:
- Publication type:
- Article
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1–3 signaling, but not FGFR4 signaling.
- Published in:
- Carcinogenesis, 2021, v. 42, n. 1, p. 58, doi. 10.1093/carcin/bgaa049
- By:
- Publication type:
- Article
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 1, p. 181, doi. 10.3390/v15010181
- By:
- Publication type:
- Article
Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-96203-z
- By:
- Publication type:
- Article
Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-88632-7
- By:
- Publication type:
- Article
Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia.
- Published in:
- Frontiers in Genetics, 2022, v. 13, p. 1, doi. 10.3389/fgene.2022.870192
- By:
- Publication type:
- Article
Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
- Published in:
- Journal of Gastroenterology, 2023, v. 58, n. 7, p. 656, doi. 10.1007/s00535-023-01993-w
- By:
- Publication type:
- Article
Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
- Published in:
- Journal of Gastroenterology, 2021, v. 56, n. 2, p. 168, doi. 10.1007/s00535-020-01750-3
- By:
- Publication type:
- Article
Durable response without recurrence to Tolvaptan improves long-term survival.
- Published in:
- Journal of Gastroenterology, 2020, v. 55, n. 12, p. 1150, doi. 10.1007/s00535-020-01721-8
- By:
- Publication type:
- Article
Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
- Published in:
- PLoS ONE, 2022, v. 17, n. 7, p. 1, doi. 10.1371/journal.pone.0270786
- By:
- Publication type:
- Article
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
- Published in:
- PLoS ONE, 2022, v. 17, n. 1, p. 1, doi. 10.1371/journal.pone.0261760
- By:
- Publication type:
- Article
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 5, p. 769, doi. 10.1007/s11523-024-01092-7
- By:
- Publication type:
- Article
Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
- Published in:
- Journal of Viral Hepatitis, 2022, v. 29, n. 11, p. 976, doi. 10.1111/jvh.13740
- By:
- Publication type:
- Article
Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass.
- Published in:
- Journal of Viral Hepatitis, 2021, v. 28, n. 5, p. 755, doi. 10.1111/jvh.13484
- By:
- Publication type:
- Article
Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.
- Published in:
- JGH Open, 2020, v. 4, n. 5, p. 880, doi. 10.1002/jgh3.12339
- By:
- Publication type:
- Article
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan.
- Published in:
- Journal of Gastroenterology & Hepatology, 2020, v. 35, n. 10, p. 1782, doi. 10.1111/jgh.15041
- By:
- Publication type:
- Article
Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.
- Published in:
- Nutrients, 2021, v. 13, n. 7, p. 2415, doi. 10.3390/nu13072415
- By:
- Publication type:
- Article